Tactile Systems (TCMD) Stock Forecast & Price Target

Tactile Systems Tech is supported by a large, under-penetrated lymphedema market, structural reimbursement tailwinds from the Medicare NCD and expected AVF guideline language, and a differentiated at-home therapy platform that is gaining adoption through Flexitouch, Nimbl, and its head-and-neck offering. The company’s 1Q26 results showed strong underlying execution, with revenue of $75.3M, lymphedema sales up 23% Y/Y, airway clearance up 22% Y/Y, and gross margin of 76.5%, while FY26 guidance points to revenue of $360M-$368M and adj. EBITDA of $49M-$51M. Management’s FY25 transformation, expanding sales force, improved CRM and back-office processes, and LymphaTech’s diagnostic capabilities should improve productivity, broaden diagnosis, and support durable top-line growth toward the HSDs.

Tactile Systems Tech is facing a pressured outlook because growth depends on commercial-channel adoption and a sales force that may not be leveraged efficiently, while reps can be distracted by non-selling tasks and Medicare documentation burdens. The company also contends with competitive pressure from Airway Clearance and inconsistent physician views on pneumatic compression as a standalone treatment, which has already forced FY26 revenue guidance down to $360M to $366M and reduced modeled sales to $363.4M. Although adjusted EBITDA remains guided at $49M to $51M and 2Q26 ended with 332 sales reps, these metrics suggest profitability is being defended more by expense control than by robust demand acceleration.